GW Pharmaceuticals PLC- ADR (GWPH) was Reiterated by Cantor Fitzgerald to “Buy” while Lowering the Price Target of the company shares to $ 165 from a previous price target of $181 . Cantor Fitzgerald advised their investors in a research report released on Aug 9, 2016.
Many Wall Street Analysts have commented on GW Pharmaceuticals PLC- ADR. Cantor Fitzgerald Initiated GW Pharmaceuticals PLC- ADR on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $181.
On the company’s financial health, GW Pharmaceuticals PLC- ADR reported $-0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.10. The company had revenue of $2.30 million for the quarter, compared to analysts expectations of $2.76 million. The company’s revenue was down -73.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.085 EPS.
GW Pharmaceuticals PLC- ADR closed down -1.66 points or -1.74% at $93.96 with 2,45,319 shares getting traded on Monday. Post opening the session at $95.37, the shares hit an intraday low of $93.71 and an intraday high of $95.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Companys product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.